DE69934583D1 - Nukleinsäure-impfstoffe zur verhinderung der flaviviren-infektion - Google Patents

Nukleinsäure-impfstoffe zur verhinderung der flaviviren-infektion

Info

Publication number
DE69934583D1
DE69934583D1 DE69934583T DE69934583T DE69934583D1 DE 69934583 D1 DE69934583 D1 DE 69934583D1 DE 69934583 T DE69934583 T DE 69934583T DE 69934583 T DE69934583 T DE 69934583T DE 69934583 D1 DE69934583 D1 DE 69934583D1
Authority
DE
Germany
Prior art keywords
flaviviren
infection
preventing
nucleic acid
acid vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69934583T
Other languages
English (en)
Other versions
DE69934583T2 (de
Inventor
J Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of DE69934583D1 publication Critical patent/DE69934583D1/de
Application granted granted Critical
Publication of DE69934583T2 publication Critical patent/DE69934583T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69934583T 1998-06-04 1999-06-03 Nukleinsäure-impfstoffe zur verhinderung der flaviviren-infektion Expired - Lifetime DE69934583T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8790898P 1998-06-04 1998-06-04
US87908P 1998-06-04
PCT/US1999/012298 WO1999063095A1 (en) 1998-06-04 1999-06-03 Nucleic acid vaccines for prevention of flavivirus infection

Publications (2)

Publication Number Publication Date
DE69934583D1 true DE69934583D1 (de) 2007-02-08
DE69934583T2 DE69934583T2 (de) 2007-10-04

Family

ID=22207979

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69934583T Expired - Lifetime DE69934583T2 (de) 1998-06-04 1999-06-03 Nukleinsäure-impfstoffe zur verhinderung der flaviviren-infektion

Country Status (9)

Country Link
US (3) US7417136B1 (de)
EP (1) EP1084252B1 (de)
JP (1) JP4489943B2 (de)
AU (1) AU778988B2 (de)
BR (1) BR9910830A (de)
CA (1) CA2331368C (de)
DE (1) DE69934583T2 (de)
IL (2) IL139844A0 (de)
WO (1) WO1999063095A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU778988B2 (en) 1998-06-04 2004-12-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Nucleic acid vaccines for prevention of flavivirus infection
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
AU3844101A (en) 2000-02-16 2001-08-27 Us Health Avirulent, immunogenic flavivirus chimeras
AU2007202304B2 (en) * 2001-04-04 2010-03-18 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION Nucleic acid vaccines for prevention of flavivirus infection
PL212212B1 (pl) 2001-07-27 2012-08-31 Wyeth Corp Kompozycja szczepionki przeciwko zakażeniu wirusem Zachodniego Nilu, kompozycja końskiej szczepionki, szczepionka wirusa Zachodniego Nilu oraz zastosowania
RU2307872C2 (ru) * 2002-10-09 2007-10-10 СиАйДи КО., ЛТД НОВАЯ ПОЛНОРАЗМЕРНАЯ ГЕНОМНАЯ PHK ВИРУСА ЯПОНСКОГО ЭНЦЕФАЛИТА, ПОЛУЧЕННАЯ ИЗ НЕЕ ИНФЕКЦИОННАЯ кДНК JEV И ИХ ПРИМЕНЕНИЕ
CA2576798C (en) 2004-07-27 2014-09-09 Gwong-Jen J. Chang Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
CA3150411C (en) 2009-07-31 2023-09-12 Pnuvax Inc. High yield yellow fever virus strain with increased propagation in cells
US20110182976A1 (en) * 2010-01-28 2011-07-28 National Taiwan Ocean University Lipoplex-patch based dna vaccine
PE20211814A1 (es) 2013-03-15 2021-09-14 Takeda Vaccines Inc Composiciones y metodos de construcciones quimericas del virus del dengue en vacunas
CN105311646B (zh) * 2015-05-05 2019-03-29 中国人民解放军第二军医大学 埃兹蛋白在防治乙型脑炎病毒感染中的应用
CN105311647B (zh) * 2015-05-05 2018-11-30 中国人民解放军第二军医大学 丝切蛋白在防治乙型脑炎病毒感染中的应用
US10947277B2 (en) 2016-06-13 2021-03-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
TWI599654B (zh) * 2016-06-24 2017-09-21 國立中興大學 日本腦炎病毒類病毒顆粒表現質體及日本腦炎ｄｎａ疫苗
US10898566B2 (en) 2016-09-19 2021-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zika virus vaccines
WO2018152526A1 (en) 2017-02-20 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Zika virus vaccines
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
MX2021002586A (es) 2018-09-05 2021-06-08 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administracion de esta.

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53133627A (en) 1977-04-25 1978-11-21 Nippon Seibutsu Kagaku Kenkiyu High purity deactivated vaccine for japanese encephalitis
JPH0768267B2 (ja) 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPS634895A (ja) 1986-06-24 1988-01-09 Mitsubishi Electric Corp オゾン精製水供給装置
JPS6325725A (ja) 1986-07-18 1988-02-03 Nec Corp アドレス表分類方式
JPS63105682A (ja) 1986-10-23 1988-05-10 Mitsubishi Kasei Corp デングウイルス３型由来のｃＤＮＡ
FR2614219B1 (fr) 1987-04-23 1993-07-09 Materiels Annexes Dialyse Procede de fabrication de granules destines a la preparation de solutions de dialyse et installation pour sa mise en oeuvre.
JPH084508B2 (ja) 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
US4783502A (en) 1987-12-03 1988-11-08 Ppg Industries, Inc. Stable nonaqueous polyurethane microparticle dispersion
JP2511494B2 (ja) 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
IL91304A0 (en) 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
JPH0425408A (ja) 1990-05-21 1992-01-29 Hitachi Ltd ペレタイジングシステムの自動連続運転制御方法
FR2665710A1 (fr) 1990-08-10 1992-02-14 Pasteur Institut Baculovirus recombinant exprimant les proteines e et ns1 de virus appartenant aux flaviviridae ou de virus apparentes aux flaviviridae, applications diagnostiques et therapeutiques.
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
ES2153223T3 (es) 1991-09-19 2001-02-16 Us Health Flavivirus quimericos y/o flavivirus de crecimiento restringido.
JPH05276941A (ja) * 1992-02-28 1993-10-26 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法
JPH07265093A (ja) 1994-03-30 1995-10-17 Chemo Sero Therapeut Res Inst 哺乳動物細胞を用いる日本脳炎ウイルス表面抗原蛋白質の製法
CA2224724C (en) 1995-05-24 2007-12-04 Hawaii Biotechnology Group, Inc. Subunit vaccine against flavivirus infection
US6136561A (en) 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
US6074865A (en) 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
WO1998017814A2 (en) * 1996-10-18 1998-04-30 Valentis Inc. Gene expression and delivery systems and uses
DE69841690D1 (de) 1997-02-28 2010-07-08 Acambis Inc Chimäre Impfstoffe gegen Flaviviren
WO1999006068A2 (en) 1997-07-31 1999-02-11 Hawaii Biotechnology Group, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
EP1047448B1 (de) * 1997-11-20 2006-02-01 United States Army Medical Research and Materiel Command Dna impfstoffe gegen zecken-flavivieren
AU778988B2 (en) 1998-06-04 2004-12-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Nucleic acid vaccines for prevention of flavivirus infection
AU2002305028A1 (en) 2001-02-28 2002-10-28 Brown University Research Foundation West nile virus epitopes and uses thereof
EP1372711A4 (de) 2001-03-12 2005-06-01 Univ Yale Zusammensetzungen und verfahren mit west-nil-virus-polypeptiden
JP5276941B2 (ja) 2008-09-24 2013-08-28 株式会社村田製作所 大変位アクチュエータ

Also Published As

Publication number Publication date
US20080241186A1 (en) 2008-10-02
WO1999063095A1 (en) 1999-12-09
CA2331368A1 (en) 1999-12-09
US7417136B1 (en) 2008-08-26
US8105609B2 (en) 2012-01-31
AU778988B2 (en) 2004-12-23
IL139844A0 (en) 2002-02-10
WO1999063095A9 (en) 2000-06-02
AU4329699A (en) 1999-12-20
US8728488B2 (en) 2014-05-20
JP2002517200A (ja) 2002-06-18
BR9910830A (pt) 2001-02-13
CA2331368C (en) 2009-02-10
DE69934583T2 (de) 2007-10-04
JP4489943B2 (ja) 2010-06-23
EP1084252A1 (de) 2001-03-21
IL139844A (en) 2008-11-03
US20120093862A1 (en) 2012-04-19
EP1084252B1 (de) 2006-12-27

Similar Documents

Publication Publication Date Title
DE69934583D1 (de) Nukleinsäure-impfstoffe zur verhinderung der flaviviren-infektion
DK1221955T3 (da) Immunstimulerende nukleinsyre
DE69900552T2 (de) Kristallisierendes Glasurkomponentensystem
NO20014325L (no) Vaksine
DE69929099D1 (de) Gerät zur Extraktion von Nukleinsäuren
PT1210113E (pt) Composicoes de vacinas de combinacao
NO20004758D0 (no) Vaksinesammensetning
NO20006191D0 (no) Vaksine
DK1100769T3 (da) Aminomethylcarboxylsyrederivater
DE60033236D1 (de) System zur vermeidung von heckcrashs bei flugzeugen
DE60002650D1 (de) Öladjuvierter Impfstoff
DK0914440T3 (da) Nukleinsyrevaccination mod parvovirusinfektioner
NO20020763L (no) Vaksine
DE60030811D1 (de) Verfahren zur Ampifizierung von RNA
FR2776928B1 (fr) Vaccins adn adjuves
DE69527328D1 (de) NUKLEINSÄUREPROBEN ZUR DETEKTION VON -i(HAEMOPHILUS INFLUENZA)
NO20005599L (no) Vaksine
DE60010034D1 (de) Methode zur handhabung von 1,1,1,3,3-pentfluoropropan
HUP0203848A3 (en) Nucleic acid vaccination
ATE295182T1 (de) Zusammensetzungen zur immunverstärkung von impfstoffen
DE50106825D1 (de) Gasgargerät zur thermischen gargutzubereitung
DE10081991D2 (de) Handhabungssystem
DE60045074D1 (de) System zur stabilisierung von proben
ITMI981384A1 (it) Vaccino per hiv
DE29803118U1 (de) Kanüle

Legal Events

Date Code Title Description
8364 No opposition during term of opposition